These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Doping]. Kamber M; Villard G Praxis (Bern 1994); 1995 Sep; 84(36):970-7. PubMed ID: 7481289 [TBL] [Abstract][Full Text] [Related]
6. Stimulants in sports. Eichner ER Curr Sports Med Rep; 2008; 7(5):244-5. PubMed ID: 18772680 [No Abstract] [Full Text] [Related]
7. [Doctors belonging to the Senegalese Association of Sport Medicine and doping in sports: survey on knowledge and attitudes]. Dièye AM; Diallo B; Fall A; Ndiaye M; Cissè F; Faye B Sante; 2005; 15(3):167-70. PubMed ID: 16207578 [TBL] [Abstract][Full Text] [Related]
9. [Many "doping pitfalls" in spite of safe measurement methods]. Nystrand A Lakartidningen; 1996 Jul; 93(28-29):2570-6. PubMed ID: 8766754 [No Abstract] [Full Text] [Related]
10. [Sports and doping]. Yoshida T Chudoku Kenkyu; 2003 Jul; 16(3):299-305. PubMed ID: 14582352 [No Abstract] [Full Text] [Related]
11. Distribution of caffeine levels in urine in different sports in relation to doping control before and after the removal of caffeine from the WADA doping list. Kuipers H Int J Sports Med; 2007 Feb; 28(2):178; author reply 178. PubMed ID: 17290310 [No Abstract] [Full Text] [Related]
12. Stimulants and sudden death: what is a physician to do? Wilens TE; Prince JB; Spencer TJ; Biederman J Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018 [TBL] [Abstract][Full Text] [Related]
13. Running on dope. Starr M Newsweek; 2004 May; 143(22):58-9. PubMed ID: 15216662 [No Abstract] [Full Text] [Related]
14. Psychotropic effects of non-psychotropic drugs. Bullinger M Adverse Drug React Acute Poisoning Rev; 1987; 6(3):141-67. PubMed ID: 2892362 [No Abstract] [Full Text] [Related]
15. Performance enhancement drugs: safe and effective? Clem JR S D J Med; 2004 Jun; 57(6):215-6. PubMed ID: 15253475 [No Abstract] [Full Text] [Related]
17. Distribution of caffeine levels in urine in different sports in relation to doping control before and after the removal of caffeine from the WADA doping list. Van Thuyne W; Delbeke FT Int J Sports Med; 2006 Sep; 27(9):745-50. PubMed ID: 16586337 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder. Newcorn JH; Donnelly C Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385 [No Abstract] [Full Text] [Related]
20. Sudden unexpected death in a female fitness athlete, with a possible connection to the use of anabolic androgenic steroids (AAS) and ephedrine. Thiblin I; Mobini-Far H; Frisk M Forensic Sci Int; 2009 Jan; 184(1-3):e7-11. PubMed ID: 19110387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]